Sofinnova Closes Crossover II Fund at €725 Million
The life sciences venture firm's new fund exceeded its original target and will back European clinical-stage biopharma and medtech companies.
Updated on Nov. 16, 2026 in Biotech

Sofinnova Partners has closed Sofinnova Crossover II at €725 million ($815 million USD), exceeding its original target. The fund is backed by the European Tech Champions Initiative, a fund of funds managed by the European Investment Fund.
Why it matters
The close gives Sofinnova fresh capital to fund clinical-stage European biopharma and medtech companies seeking to reach commercialization. It also signals continued investor appetite for late-stage life sciences venture funding in Europe.
The fund's final close totaled €725 million ($815 million USD) and is projected to fund approximately 15 companies across its investment period. The original fundraising target was exceeded, though the exact target amount was not disclosed.
The players
Sofinnova Partners
Sofinnova Partners is a life sciences venture capital firm founded in 1972 and headquartered in Paris, with offices in London and Milan, that has backed more than 500 companies.
European Investment Fund
The European Investment Fund is a European Union-backed financial institution that manages fund-of-funds programs to support small and mid-sized enterprises across Europe.
The details
Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization, while also investing selectively in best-in-class companies in the United States and other international markets. The strategy is led by Partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat, and David Evans.
Timeline
• November 15, 2026: Sofinnova issued a press release announcing the final close of Crossover II.
Tech Race
The close fits a broader pattern in which European life sciences investors rely on public-backed fund-of-funds programs such as the European Tech Champions Initiative to fill late-stage capital gaps. Sofinnova's earlier Crossover I fund supported companies later acquired by Inari Medical, Asahi Kasei and AstraZeneca, as well as Abivax's Nasdaq listing.
For patients and clinicians, a funded pipeline of European clinical-stage therapies and medical devices may eventually translate into new treatment options, though timelines from venture investment to market availability are typically long. The fund's investments are not expected to change near-term access to any product.
The takeaway
Venture capital backing for clinical-stage companies is a long-horizon bet, and fund closings like this one mainly indicate where investors expect future therapies and devices to come from. Readers following biotech funding can track portfolio company milestones over the coming years to gauge results.
Further reading
Explore more Biotech coverage for context on how venture funding is shaping drug and device development.







